GoAI
Get started
Rafael Holdings, Inc. logo

Rafael Holdings, Inc.

RFL

NYSEReal EstateReal Estate - Services

Open in GoAI

Previous close

$2.16

+$0.31 · +16.76%

Aug 21, 4:00 PM ET

RFL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

53

Fair Value

Momentum

72

Gaining

Sentiment

60

Mixed

Risk resilience

38

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

Industry
Real Estate - Services
Sector
Real Estate
Headquarters
US
CEO
Howard S. Jonas
Listed since
Mar 27, 2018
Employees
22

Market position

Day range

Current $2.16

52-week range

Current $2.16

Open
$1.85
Previous close
$1.85
Volume
142.04K
0.86× average
Average volume
164.68K
Average daily volume
Market cap
110.62M USD
Beta
0.35
Market reference 1
50-day average
$2.3116
-6.56% below average
200-day average
$1.543
+39.98% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-3.16×
P/B (TTM)
1.47×
P/S (TTM)
112.88×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
84.39%
Operating margin
-3717.24%
Net margin
-3321.73%

Financial health

Debt / equity
0.01×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends3150%-9051%-21253%-33455%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 75.82%Gross margin, FY2025: 53.98%Operating margin, FY2021: -2643.27%Operating margin, FY2022: -14750.49%Operating margin, FY2023: -5391.76%Operating margin, FY2024: -16110.99%Operating margin, FY2025: -2847.22%Net margin, FY2021: -3060.35%Net margin, FY2022: -30404.39%Net margin, FY2023: -672.40%Net margin, FY2024: -5401.88%Net margin, FY2025: -3328.24%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 75.82%. Gross margin FY2025 53.98%. Operating margin FY2021 -2643.27%. Operating margin FY2022 -14750.49%. Operating margin FY2023 -5391.76%. Operating margin FY2024 -16110.99%. Operating margin FY2025 -2847.22%. Net margin FY2021 -3060.35%. Net margin FY2022 -30404.39%. Net margin FY2023 -672.40%. Net margin FY2024 -5401.88%. Net margin FY2025 -3328.24%.

Income trends

Revenue

917K USD+43.96%

Operating income

−26.11M USD+74.56%

Net income

−30.52M USD+11.30%
Income trends across reported periods13.47M USD−36.76M USD−86.99M USD−137.22M USDRevenue, FY2021: 802K USDRevenue, FY2022: 410K USDRevenue, FY2023: 279K USDRevenue, FY2024: 637K USDRevenue, FY2025: 917K USDOperating income, FY2021: −21.2M USDOperating income, FY2022: −60.48M USDOperating income, FY2023: −15.04M USDOperating income, FY2024: −102.63M USDOperating income, FY2025: −26.11M USDNet income, FY2021: −24.54M USDNet income, FY2022: −124.66M USDNet income, FY2023: −1.88M USDNet income, FY2024: −34.41M USDNet income, FY2025: −30.52M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 802K USD. Revenue FY2022 410K USD. Revenue FY2023 279K USD. Revenue FY2024 637K USD. Revenue FY2025 917K USD. Operating income FY2021 −21.2M USD. Operating income FY2022 −60.48M USD. Operating income FY2023 −15.04M USD. Operating income FY2024 −102.63M USD. Operating income FY2025 −26.11M USD. Net income FY2021 −24.54M USD. Net income FY2022 −124.66M USD. Net income FY2023 −1.88M USD. Net income FY2024 −34.41M USD. Net income FY2025 −30.52M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue917K USD637K USD279K USD410K USD802K USD
Cost of goods sold422K USD154K USD——70K USD
Gross profit495K USD483K USD279K USD410K USD802K USD
Research and development12.82M USD94.03M USD6.31M USD8.74M USD4.91M USD
Selling, general, and administrative13.78M USD8.85M USD8.93M USD16.98M USD20.42M USD
Operating expenses26.6M USD103.11M USD15.32M USD60.89M USD29M USD
Interest income2M USD2.38M USD3.25M USD201K USD2K USD
Interest expense658K USD248K USD—6K USD12K USD
Depreciation and amortization288K USD225K USD78K USD72K USD70K USD
Operating income−26.11M USD−102.63M USD−15.04M USD−60.48M USD−21.2M USD
Net income−30.52M USD−34.41M USD−1.88M USD−124.66M USD−24.54M USD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.15

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-0.05-0.17-0.29-0.41Q4 '24Q4 '24Q1 '25Q2 '25Q4 '25Q4 '25Q1 '26Q2 '26
Q4 2024, reported Nov 6, 2024: actual -0.19, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Dec 11, 2024: actual -0.37, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 13, 2025: actual -0.06, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Jun 11, 2025: actual -0.19, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Oct 29, 2025: actual -0.28, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Dec 11, 2025: actual -0.19, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 16, 2026: actual -0.13, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Jun 11, 2026: actual -0.15, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates384.8K278.35K171.9K65.45KQ4 '24Q4 '24Q1 '25Q2 '25Q4 '25Q4 '25Q1 '26Q2 '26
Q4 2024, reported Nov 6, 2024: actual 165K USD, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Dec 11, 2024: actual 128K USD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 13, 2025: actual 77K USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Jun 11, 2025: actual 362K USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Oct 29, 2025: actual 350K USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Dec 11, 2025: actual 240K USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 16, 2026: actual 211K USD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Jun 11, 2026: actual 179K USD, estimate —, surprise —, Comparison unavailable.

RFL news

newsfilecorp.com

Nuclea Energy USA Inc. Announces MOU with Utah Office of Energy Development

The MOU supports exploration of a nuclear test reactor site at the Utah San Rafael Energy Lab to advance the Morpheus microreactor toward demonstration and deployment Salt Lake City, Utah--(Newsfile Corp. - August 5,…

Read source
defenseworld.net

Head to Head Comparison: Oncology Pharma (OTCMKTS:ONPH) & Rafael (NYSE:RFL)

Rafael (NYSE: RFL - Get Free Report) and Oncology Pharma (OTCMKTS:ONPH - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength…

Read source
newsfilecorp.com

Manhattan Uranium Identifies High-Grade Uranium Intercepts from 5,668-Hole Database Compilation at I-70, San Rafael District, Utah

72% of Drilled Holes Return Uranium Mineralization; 3D Drill Targets Generated Across Historical Utah Uranium District Vancouver, British Columbia--(Newsfile Corp. - July 23, 2026) - Manhattan Uranium Discovery Corp.…

Read source
accessnewswire.com

Sekur Private Data Appoints Special Operations Communications Chief Master Sergeant (Ret.) Rafael Beltran to Its OpsTech Special Advisory Board

Former SOCOM Senior Technical Advisor to CIO/J6 and Executive Communications Chief to Guide Sekur's Tactical Technology Strategy for Defense, Intelligence and Government Markets MIAMI, FL / ACCESS Newswire / July 7, 2026…

Read source
newsfilecorp.com

AuMEGA Metals Appoints Rafael Gradim as President

Highly accomplished executive with extensive exploration, strategy, corporate development and capital markets experience to lead exploration Edmonton, Alberta--(Newsfile Corp. - July 6, 2026) - AuMEGA Metals Ltd. (ASX:…

Read source
seekingalpha.com

Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever

Rafael Holdings' Phase 3 clinical trial of a drug named Trappsol Cyclo just got over. Results of the trial are expected in the second half of 2026. RFL has a runway of 4 to 5 quarters. RFL could end up borrowing money in…

Read source

Corporate actions

Corporate action history

Dividend

Ex-dividend Dec 18, 2009

$0.02

Semi-Annual

Payment Dec 31, 2009

Dividend

Ex-dividend Jun 19, 2009

$0.02

Semi-Annual

Payment Jun 30, 2009

RFL peers

Welltower Inc. logo

WELL

Welltower Inc.

$239.3

+0.80%

Prologis, Inc. logo

PLD

Prologis, Inc.

$141.8

+0.79%

American Tower Corporation logo

AMT

American Tower Corporation

$175.8

+0.05%

Simon Property Group, Inc. logo

SPG

Simon Property Group, Inc.

$218.29

-0.73%

Digital Realty Trust, Inc. logo

DLR

Digital Realty Trust, Inc.

$190.62

-1.89%

Public Storage logo

PSA

Public Storage

$322.49

-0.08%

ETFs holding RFL

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.89M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
920.4K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
218.72K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
171.52K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
59.91K
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%
Dimensional - US Core Equity 2 ETF logoDimensional - US Core Equity 2 ETFDFAC
Market value
35.05K
Weight
0.00%
AUM
49.31B USD
Expense ratio
0.17%
Price / 1D
$45.61+0.46%
Avantis U.S. Small Cap Equity ETF logoAvantis U.S. Small Cap Equity ETFAVSC
Market value
20.33K
Weight
—
AUM
3.16B USD
Expense ratio
0.25%
Price / 1D
$73.84+0.70%
Dimensional - US Vector Equity ETF logoDimensional - US Vector Equity ETFDXUV
Market value
7.37K
Weight
0.00%
AUM
578.74M USD
Expense ratio
0.28%
Price / 1D
$69.80+0.69%

Continue in GoAI

Research RFL

research.disclaimer